MINERALYS THERAPEUTICS, INC. Stock Split Ratio
MINERALYS THERAPEUTICS, INC. (MLYS) reported Stock Split Ratio of 92.60% for the 1-month period ending 2023-02-28, per its 10-K filed 2024-03-21.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2025-02-12
- 2023-02-28: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 92.60%.
- 2023-02-01: Stockholders' Equity Note, Stock Split, Conversion Ratio 9.26%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2023-02-28 | 92.60% 10-K · filed 2024-03-21 | |
| 2023-02-01 | 9.26% 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |